AB Therapeutics Hires José Alfón as Director of Development
Alfón, previously at Palau Pharma, will head the Catalan company’s preclinical and clinical development of an anti-cancer drug candidate
Catalan biotechnology company AB Therapeutics, an independent subsidiary of AB-Biotics that focuses on drug development, has just hired José Alfón as Director of Development. Alfón previously served as Project Leader at Palau Pharma.
In bringing Alfón aboard, AB Therapeutics has finished putting together a solid team of scientists with broad international experience. His mission will be to direct the company’s recently begun preclinical development program for an anti-cancer drug candidate through the clinical phase.
José Alfón, 43, earned a Bachelor of Pharmacy and an MS in Pharmaceutical Sciences from the Hebrew University of Jerusalem, and a PhD in Pharmaceutical Sciences from the University of Barcelona (UB). He has over ten years experience in identifying drug candidates and in developing drugs from the discovery stage to Phase II clinical trials. In addition to Palau Pharma, where has spent most of his career to date, he has also held various research positions at the Hebrew University of Jerusalem, the Spanish National Research Council (CSIC), and different hospitals in the UK and Israel.
AB Therapeutics is located at the UAB Research Park. It was co-founded by Carles Domènech (CEO), Jordi Espadaler (Director of Research) and AB-Biotics.